The FINANCIAL -- Sanofi and Bristol-Myers Squibb Company announced that Apotex has made payment in the amount of $442,209,362 to satisfy the damages ruling of the Plavix patent infringement case against Apotex.

According to Sanofi, this payment, which follows the decision of the U.S. Court of Appeals for the Federal Circuit in October 2011 upholding the payment of damages to the companies by Apotex, represents the final phase of the Plavixpatent litigation between the companies and Apotex, which was initiated in March 21, 2002.

Sanofi and Bristol-Myers Squibb were also awarded $1,258,682 in post-judgment interest and $900,000 in costs in addition to the damages award.

Sanofi and Bristol-Myers Squibb are pleased that their intellectual property rights have been upheld and that Apotex has made reparation of the harm caused by the at-risk launch of a generic version of clopidogrel bisulfate in 2006.

Related Stories

• FDA Advisory Committee Finds Data Support Effectiveness of Tafamidis Meglumine
• Pfizer Names Olivier Brandicourt as President and General Manager
• Janssen Healthcare Innovation Announces Discharge Decision Support System Winner